Platinum-etoposide chemotherapy

Author: snmr

August undefined, 2024

Webb1 dec. 2024 · Methods Five consecutive ACC patients treated with platinum etoposide (120-150 mg/m2 day 1-2-3 at cycle 1), with or without concomitant mitotane, were … Webb4 sep. 2024 · Chemotherapy regimens containing platinum represent the cornerstone of treatment for patients with extensive disease, but there has been no real progress for 30 years. The evidence that SCLC is characterized by a high mutational burden led to the development of immune-checkpoint inhibitors as single agents or in combination with …

Update 2024: Management of Small Cell Lung Cancer - PubMed

Webb6 juli 2024 · Phase II Trial of Platinum-Etoposide Chemotherapy and Durvalumab (MEDI4736) With Sub-Ablative SBRT in Patients With Newly Diagnosed Stage IV Small … Webb18 juli 2024 · For over 30 years, platinum-based chemotherapy has remained the primary therapeutic option for patients with SCLC. The recent CASPIAN and IMpower133 studies on the effectiveness of the combination of chemotherapy and immunotherapy in this group of patients have opened a completely new chapter in SCLC treatment. h giagia mas h kali

Immunotherapy in Small Cell Lung Cancer - European Medical …

Webb20 jan. 2005 · Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose … Webb13 jan. 2024 · Based on results of the pivotal IMpower133 study, atezolizumab (anti–programmed death-ligand 1 [anti–PD-L1]) in combination with carboplatin and etoposide (CP/ET) was approved for the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). WebbBackground: Patients with limited-stage (ls) or extensive-stage (es) small-cell lung cancer (sclc) are commonly given platinum-based chemotherapy as first-line treatment. Standard chemotherapy for patients with ls sclc includes a platinum agent such as cisplatin combined with the non-platinum agent etoposide. hgi atd 31

First-line atezolizumab/durvalumab plus platinum–etoposide …

Etoposide and cisplatin chemotherapy (EP) Macmillan Cancer Support

WebbFirst-line platinum-based combined chemotherapy was clustered as “NSCLC-t”, comprising gemcitabine, docetaxel, paclitaxel or vinorelbine; “NSCLC-pt”, with pemetrexed treatment only; and “SCLC-t”, consisting of … Webb1 dec. 2024 · We primarily evaluated the progression-free survival (PFS) and overall survival (OS) outcomes in association with atezolizumab compared with platinum … hgi bahrain bayWebb11 apr. 2024 · Platinum-based chemotherapy has been the standard first-line treatment for both limited-stage (LS) and extensive-stage (ES) disease since the 1980s, with an objective response rate (ORR) of about 65% and a one-year survival rate of 30%-40% for ES-SCLC ( … hgiap l'isle adam

"Webb28 feb. 2024 · In recent years, programmed cell death-ligand 1 (PD-L1) inhibitor plus platinum-etoposide chemotherapy was found to have favorable clinical outcomes in patients with extensive-stage SCLC (ES-SCLC). The usefulness of early tumor shrinkage (ETS) has been reported in various types of cancers. " - Platinum-etoposide chemotherapy

Platinum-etoposide chemotherapy

Initial management of small-cell lung cancer (limited- and …

Webb10 apr. 2024 · Let’s discuss the CASPIAN trial [NCT03043872]. The CASPIAN trial assessed durvalumab, which is an anti-PD-L1 antibody, with or without tremelimumab [Imjudo], which is a CTLA-4 antibody in combination with chemotherapy and platinum and etoposide chemotherapy in extensive-stage small cell lung cancer patients. Webb6 apr. 2024 · First-line chemoimmunotherapy was administered as early as possible after diagnosis: four to six cycles of etoposide plus carboplatin or cisplatin combined with …

Did you know?

WebbEtoposide and cisplatin chemotherapy (EP) is a combination chemotherapy treatment used to treat different types of cancer. It is best to read this information with our general … Webb23 nov. 2024 · Platinum-etoposide consisted of etoposide 80-100 mg/m2on days 1-3 of each cycle with investigator's choice of either carboplatin area under the curve 5-6 …

WebbAdjuvant chemotherapy with a platinum/etoposide-containing regimen should be used in women with metastatic disease. All 5 women with ETT in this series were cured using … Webb1 juli 2024 · Currently, programmed death-ligand 1 (PD-L1) inhibitor plus platinum-etoposide chemotherapy has been recognized as a standard treatment for patients with …

Webb27 okt. 2024 · Of the 34 patients who received atezolizumab, 24% had Eastern Cooperative Oncology Group performance status greater than or equal to 2, approximately 50% were …

Webb21 sep. 2016 · Platinum-Etoposide Chemotherapy in Elderly Patients With Small-Cell Lung Cancer: Results of a Randomized Multicenter Phase II Study Assessing Attenuated-Dose …

Webb8 apr. 2024 · In keeping with this, treatment of metastatic disease with platinum-etoposide chemotherapy mirrors small-cell lung cancer treatment recommendations. However, clinical course and best treatment strategy are far from being clear. h gianniniWebb11 apr. 2024 · BackgroundThere are a variety of treatment options for recurrent platinum-resistant ovarian cancer, and the optimal specific treatment still remains to be determined. Therefore, this Bayesian network meta-analysis was conducted to investigate the optimal treatment options for recurrent platinum-resistant ovarian cancer.MethodsPubmed, … hgi-atd 31Webb13 juni 2024 · Based on this Phase II randomised trial, phased ipilimumab was investigated in the following Phase III study. 18 In this trial, 1,132 patients were assigned to a platinum/etoposide regimen for 4–6 cycles plus phased ipilimumab 10 mg/kg or placebo every 3 weeks followed by a maintenance phase of ipilimumab 10 mg/kg or placebo … hgianWebbUntil June, 2024, topotecan was the only approved drug for patients with sensitive relapsed small-cell lung cancer who progressed after platinum-based chemotherapy. Topotecan … hgi b2bWebb11 apr. 2024 · All patients received platin-based chemotherapy with either carboplatin or cisplatin together with etoposide. At least one cycle of atezolizumab or durvalumab was administered, in most cases from the second or third cycle onwards. Immunotherapy with PD-L1 inhibitors was discontinued in case of adverse effects or disease progression. hgi batubaraWebbSafety and efficacy of platinum agents plus etoposide for patients with small cell lung cancer with interstitial lung disease The combination of platinum agents plus etoposide … ez dock bumper kitWebb5 dec. 2024 · Prospective evaluation of the effect on initial brain metastases from small cell lung cancer of platinum-etoposide based induction chemotherapy followed by an alternating multidrug regimen. Ann Oncol 1993; 4:579. Twelves CJ, Souhami RL, Harper PG, et al. The response of cerebral metastases in small cell lung cancer to systemic … hgi atd31